Immune-related adverse events (irAEs) associated with PD-1/PD-L1 inhibitors are well characterized and include dermatitis, colitis, hepatitis, pneumonitis, and endocrine dysfunction (thyroiditis, hypophysitis), which can usually be treated with corticosteroids or immunosuppression [130,131]. The gene discussed is PDCD1; the disease is Hepatitis.